Advertisement
Original article| Volume 61, ISSUE 5, P713-719, March 01, 2007

Meta-Analysis of Aggression or Hostility Events in Randomized, Controlled Clinical Trials of Atomoxetine for ADHD

Published:September 25, 2006DOI:https://doi.org/10.1016/j.biopsych.2006.05.044

      Background

      We systematically examined potential aggression/hostility-related events in a meta-analysis of acute clinical trials of atomoxetine for attention-deficit/hyperactivity disorder (ADHD).

      Methods

      Pediatric patients from 14 trials of atomoxetine were subdivided into a placebo-controlled (atomoxetine n = 1308, placebo n = 806) or active comparator databases (atomoxetine n = 566, methylphenidate n = 472). A third database comprised adult patients from placebo-controlled studies (atomoxetine n = 541, placebo n = 405). A computerized search of adverse events and comments identified patients with potential aggression/hostility events. Mantel–Haenszel incidence differences (MHID) were calculated.

      Results

      In the placebo-controlled database, we observed 21 atomoxetine and 9 placebo patients with reported aggression/hostility events, MHID of .6% (95% confidence interval [CI]: –.4, 1.7). In the active comparator database, there were seven events in atomoxetine and four in methylphenidate patients, MHID = .2% (95% CI: –1.0,1.3). In the adult database, there were no events in 0 atomoxetine and one placebo patient, MHID = –.3% (95% CI: –.8, .2).

      Conclusions

      Aggression/hostility-related events occurred in less than 2% of patients and were more frequent in pediatric patients treated with atomoxetine versus placebo (risk ratio of 1.33; not statistically significant). The risk of aggression/hostility events was similar in patients treated with atomoxetine or methylphenidate.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Agresti A.
        Analysis of ordinal categorical data. Wiley, New York1984
        • Barkley R.A.
        • Murphy K.R.
        • Dupaul G.I.
        • Bush T.
        Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive funtioning.
        J Int Neuropsychol Soc. 2002; 8: 655-672
        • Bymaster F.P.
        • Katner J.S.
        • Nelson D.L.
        • Hemrick-Luecke S.K.
        • Threlkeld P.G.
        • Heiligenstein J.H.
        • et al.
        Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
        Neuropsychopharmacol. 2002; 27: 699-711
        • Conners C.K.
        • Erhardt D.
        • Sparrow E.
        Conners’ Adult ADHD Rating Scales (CAARS). Multi-Health Systems, North Tonawanda, NY1999
        • Cunningham C.E.
        • Siegel L.S.
        • Offord D.R.
        A dose-response analysis of the effects of methylphenidate on the peer interactions and simulated classroom performance of ADD children with and without conduct problems.
        J Child Psychol Psychiatry. 1991; 32: 439-452
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Eli Lilly and Company
        Strattera [package insert]. Author, Indianapolis, IN2005
        • Fingerhut L.A.
        • Ingram D.D.
        • Feldman J.J.
        Homicide rates among US teenagers and young adults: differences by mechanism, level of urbanization, race, and sex, 1987 through 1995.
        JAMA. 1998; 280: 423-427
        • First M.B.
        • Spitzer G.M.
        • Spitzer R.L.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version. Biometrics Research, New York State Psychiatric Institute, New York, NY2000
        • Greenland S.
        • Robins J.M.
        Estimation of a common effect parameter from sparse follow-up data.
        Biometrics. 1985; 41: 55-68
        • Haller J.
        Alpha-2 adrenoceptor blockade and the response to intruder aggression in Long-Evans rats.
        Physiol Behav. 1995; 58: 101-106
        • Henderson T.A.
        • Hartman K.
        Aggression, mania, and hypomania induction associated with atomoxetine.
        Pediatrics. 2004; 114: 895-896
        • Hinshaw S.P.
        • Henker B.
        • Whalen C.K.
        • Erhardt D.
        • Dunnington Jr, R.E.
        Aggressive, prosocial, and nonsocial behavior in hyperactive boys: Dose effects of methylphenidate in naturalistic settings.
        J Consult Clin Psychol. 1989; 57: 636-643
        • Kaufman J.
        • Birmaher B.
        • Brent D.
        • Rao U.
        • Flynn C.
        • Moreci P.
        • et al.
        Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data.
        J Am Acad Child Adolesc Psychiatry. 1997; 36: 980-988
        • Kazdin A.E.
        • Rodgers A.
        • Colbus D.
        • Siegel T.
        Children’s Hostility Inventory: measurement of aggression and hostility in psychiatric inpatient children.
        J Clin Child Psychol. 1987; 16: 320-328
        • Kelsey D.K.
        • Sumner C.R.
        • Casat C.D.
        • Coury D.L.
        • Quintana H.
        • Saylor K.E.
        • et al.
        Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial.
        Pediatrics. 2004; 114: e1-e8
        • Lahey B.B.
        • Schwab-Stone M.
        • Goodman S.H.
        • Waldman I.D.
        • Canino G.
        • Rathouz P.J.
        • et al.
        Age and gender differences in oppositional behavior and conduct problems: a cross-sectional household study of middle childhood and adolescence.
        J Abnorm Psychol. 2000; 109: 488-503
        • Landis J.R.
        • Koch G.G.
        The measurement of observer agreement for categorical data.
        Biometrics. 1977; 33: 159-174
        • Lederhendler I.I.
        Aggression and violence: perspectives on integrating animal and human research approaches.
        Horm Behav. 2003; 44: 156-160
        • McGough J.J.
        • Biederman J.
        • Wigal S.B.
        • Lopez F.A.
        • McCracken J.T.
        • Spencer T.
        • et al.
        Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 530-538
        • Michelson D.
        • Adler L.
        • Spencer T.
        • Reimherr F.W.
        • West S.A.
        • Allen A.J.
        • et al.
        Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies.
        Biol Psychiatry. 2003; 53: 112-120
        • Michelson D.
        • Allen A.J.
        • Busner J.
        • Casat C.
        • Dunn D.
        • Kratochvil C.
        • et al.
        Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
        Am J Psychiatry. 2002; 159: 1896-1901
        • Michelson D.
        • Faries D.
        • Wernicke J.
        • Kelsey D.
        • Kendrick K.
        • Sallee F.R.
        • Spencer T.
        Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study.
        Pediatrics. 2001; 108: e83
        • Moffitt T.E.
        Juvenile delinquency and attention deficit disorder: Boys’ developmental trajectories from age 3 to age 15.
        Child Dev. 1990; 61: 893-910
        • MTA Cooperative Group
        A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.
        Arch Gen Psychiatry. 1999; 56: 1073-1086
        • Nagin D.
        • Tremblay R.E.
        Trajectories of boys’ physical aggression, opposition, and hyperactivity on the path to physically violent and nonviolent juvenile delinquency.
        Child Dev. 1999; 70: 1181-1196
        • Nansel T.R.
        • Overpeck M.
        • Pilla R.S.
        • Ruan W.J.
        • Simons-Morton B.
        • Scheidt P.
        Bullying behaviors among US youth: Prevalence and association with psychosocial adjustment.
        JAMA. 2001; 285: 2094-2100
        • Paternite C.E.
        • Loney J.
        • Salisbury H.
        • Whaley M.A.
        Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes.
        J Child Adolesc Psychopharmacol. 1999; 9: 169-184
        • Rivara F.P.
        • Shepherd J.P.
        • Farrington D.P.
        • Richmond P.W.
        • Cannon P.
        Victim as offender in youth violence.
        Ann Emerg Med. 1995; 26: 609-614
        • Sanson A.
        • Smart D.
        • Prior M.
        • Oberklaid F.
        Precursors of hyperactivity and aggression.
        J Am Acad Child Adolesc Psychiatry. 1993; 32: 1207-1216
        • Silver J.M.
        • Yudofsky S.C.
        The Overt Aggression Scale: Overview and guiding principles.
        J Neuropsychiatry Clin Neurosci. 1991; 3: S22-S29
        • Spencer T.
        • Heiligenstein J.H.
        • Biederman J.
        • Faries D.E.
        • Kratochvil C.J.
        • Conners C.K.
        • Potter W.Z.
        Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
        J Clin Psychiatry. 2002; 63: 1140-1147
        • Spielberger C.D.
        • Jacobs G.
        • Russell S.
        • Crane R.S.
        Assessment of anger: The state-trait anger scale.
        in: Butcher J.N. Spielberger C.D. Advances in Personality Assessment. Erlbaum, Hillsdale, NJ1983: 161-189
        • Straus S.E.
        • Richardson W.S.
        • Glasziou P.
        • Haynes R.B.
        Evidence-based medicine: how to practice and teach EBM. 3rd ed. Churchill Livingstone, London2005
        • Tremblay R.E.
        • Nagin D.S.
        • Seguin J.R.
        • Zoccolillo M.
        • Zelazo P.D.
        • Boivin M.
        • et al.
        Physical aggression during early childhood: trajectories and predictors.
        Pediatrics. 2004; 114: e43-e50
        • Turgay A.
        Aggression and disruptive behavior disorders in children and adolescents.
        Expert Rev Neurother. 2004; 4: 623-632
        • Turgay A.
        • Morgan A.
        • Mok L.
        • Ng D.
        Chronic and serious aggressive behavior in children and adolescents are commonly associated with psychiatric disorders.
        Paediatr Child Health. 2001; 6: 14
        • van der Vegt B.J.
        • Lieuwes N.
        • Cremers T.I.F.H.
        • de Boer S.F.
        • Koolhaas J.M.
        Cerebrospinal fluid monoamine and metabolite concentrations and aggression in rats.
        Horm Behav. 2003; 44: 199-208
        • Walker J.L.
        • Lahey B.B.
        • Hynd G.W.
        • Frame C.L.
        Comparison of specific patterns of antisocial behavior in children with conduct disorder with or without coexisting hyperactivity.
        J Consult Clin Psychol. 1987; 55: 910-913
        • Weiss M.
        • Tannock R.
        • Kratochvil C.
        • Dunn D.
        • Velez-Borras J.
        • Thomason C.
        • et al.
        A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 647-655
        • Wilens T.
        • McBurnett K.
        • Stein M.
        • Lerner M.
        • Spencer T.
        • Wolraich M.
        ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 1015-1023